The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
Abstract
CONTEXT: The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin are licensed to treat chemotherapy-associated anemia in patients with nonmyeloid malignancies. Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs. OBJECTIVE: To evaluate VTE and mortality rates associated with ESA administration for the treatment of anemia among patients with cancer. DATA SOURCES: A published overview from the Cochrane Collaboration (search dates: January 1, 1985-April 1, 2005) and MEDLINE and EMBASE databases (key words: clinical trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Food and Drug Administration and ESA manufacturers, and safety advisories (search dates: April 1, 2005-January 17, 2008). STUDY SELECTION: Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer. DATA EXTRACTION: Mortality rates, VTE rates, and 95% confidence intervals (CIs) were extracted by 3 reviewers from 51 clinical trials with 13 611 patients that included survival information and 38 clinical trials with 8172 patients that included information on VTE. DATA SYNTHESIS: Patients with cancer who received ESAs had increased VTE risks (334 VTE events among 4610 patients treated with ESA vs 173 VTE events among 3562 control patients; 7.5% vs 4.9%; relative risk, 1.57; 95% CI, 1.31-1.87) and increased mortality risks (hazard ratio, 1.10; 95% CI, 1.01-1.20). CONCLUSIONS: Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of VTE and mortality. Our findings, in conjunction with basic science studies on erythropoietin and erythropoietin receptors in solid cancers, raise concern about the safety of ESA administration to patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Interaction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Vansteenkiste, J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1211 · Cited by 477
Breast cancer trial with erythropoietin terminated unexpectedly
Leyland-Jones, B. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01163-x · Cited by 474
Wright, J. R., Ung, Y. C., Julian, J. A., Pritchard, K. I., Whelan, T. J., Smith, C., Szechtman, B., Roa, W., Mulroy, L., Rudinskas, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1514 · Cited by 428
Erythropoietin or darbepoetin for patients with cancer
Tonia, T., Mettler, A., Robert, N., Schwarzer, G., Seidenfeld, J., Weingart, O., Hyde, C., Engert, A., & Bohlius, J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003407.pub5 · Cited by 392
Rizzo, J. D., Somerfield, M. R., Hagerty, K. L., Seidenfeld, J., Bohlius, J., Bennett, C. L., Cella, D. F., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3396 · Cited by 327
Self-citationDo Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
Henke, M., Mattern, D., Pepe, M., Bézay, C., Weissenberger, C., Werner, M., & Pajonk, F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2737 · Cited by 240
Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennett, C., & Engert, A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji087 · Cited by 238
Self-citationErythropoietin Biology in Cancer
Hardee, M. E., Arcasoy, M. O., Blackwell, K. L., Kirkpatrick, J. P., & Dewhirst, M. W. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1771 · Cited by 223
Witzig, T. E., Silberstein, P. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., Mailliard, J. A., Rowland, K. M., Alberts, S. R., Krook, J. E., Levitt, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.020 · Cited by 209
Osterborg, A., Boogaerts, M., Cimino, R., Essers, U., Holowiecki, J., Juliusson, G., Jager, G., Najman, A., & Peest, D. (1996) · Blood · doi:10.1182/blood.v87.7.2675.bloodjournal8772675 · Cited by 202
Cascinu, S., Fedeli, A., Ferro, E. D., Fedeli, S. L., & Catalano, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1058 · Cited by 194
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
Dammacco, F., Castoldi, G., & Rödjer, S. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02715.x · Cited by 181
Henry, D. H., & Abels, R. I. (1994) · PubMed · Cited by 175
Wilson, J., Yao, G., Raftery, J., Bohlius, J., Brunskill, S., Sandercock, J., Bayliss, S., Moss, P., Stanworth, S., & Hyde, C. (2007) · Health Technology Assessment · doi:10.3310/hta11130 · Cited by 173
Thomas, G., Ali, S., Hoebers, F. J. P., Darcy, K. M., Rodgers, W. H., Patel, M., Abulafia, O., Lucci, J. A., & Begg, A. C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.10.011 · Cited by 169
Lai, S. Y., Childs, E. E., Xi, S., Coppelli, F. M., Gooding, W. E., Wells, A., Ferris, R. L., & Grandis, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1208635 · Cited by 167
Kotasek, D., Steger, G. G., Faught, W., Underhill, C. R., Poulsen, E., Colowick, A. B., Rossi, G., & Mackey, J. A. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00456-8 · Cited by 139
Mastro, L. D., Venturini, M., Lionetto, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2715 · Cited by 130
Thatcher, N. J., Campos, E. S. D., Bell, D., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690369 · Cited by 129
Machtay, M. X., Pajak, T. F., Suntharalingam, M., Shenouda, G., Hershock, D. M., Stripp, D. C. H., Cmelak, A. J., Schulsinger, A., & Fu, K. K. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.063 · Cited by 114
O’Shaughnessy, J., Vukelja, S. J., Holmes, F. A., Savin, M. A., Jones, M., Royall, D. R., George, M. J., & Hoff, D. D. V. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.002 · Cited by 114
Erythropoietin Signaling Promotes Invasiveness of Human Head and Neck Squamous Cell Carcinoma
Mohyeldin, A., Lu, H., Dalgard, C. L., Lai, S. Y., Cohen, N. A., Ács, G., & Verma, A. M. (2005) · Neoplasia · doi:10.1593/neo.04685 · Cited by 110
The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events
Rosenzweig, M. Q., Bender, C. M., Lucke, J. P., Yasko, J. M., & Brufsky, A. (2004) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2003.06.010 · Cited by 93
Grote, T., Yeilding, A., Castillo, R., Butler, D. R., Fishkin, E., Henry, D. H., Deleo, M. J., Fink, K., & Sullivan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.8507 · Cited by 92
Functional Erythropoietin Autocrine Loop in Melanoma
Kumar, S., Ács, G., Fang, D., et al. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62303-6 · Cited by 83
Ács, G., Chen, M., Xu, X., Acs, P. I., Verma, A. M., & Koch, C. J. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.04.027 · Cited by 76
for the Aranesp® 990111 Study Group, Smith, R. E., Tchekmedyian, N. S., Chan, D., Meza, L., Northfelt, D., Patel, R., Austin, M., Colowick, A. B., Rossi, G., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600994 · Cited by 75
Erythropoietin, the FDA, and Oncology
Steinbrook, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmp078100 · Cited by 62
Österborg, A., Brandberg, Y., & Hedenus, M. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05440.x · Cited by 57
Bamias, A., Aravantinos, G., Kalofonos, H. P., Timotheadou, N., Siafaka, V., Vlahou, I., Janinis, D., Pectasides, D., Pavlidis, N. A., & Fountzilas, G. (2003) · Oncology · doi:10.1159/000067766 · Cited by 51
Does Erythropoietin Have a Dark Side? Epo Signaling and Cancer Cells
Sytkowski, A. J. (2007) · Science s STKE · doi:10.1126/stke.3952007pe38 · Cited by 51
for the EPO-INT-45 Study Group, Wilkinson, P. M., Antonopoulos, M., Lahousen, M., Lind, M., & Kosmidis, P. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603004 · Cited by 49
Understanding the Presence and Function of Erythropoietin Receptors on Cancer Cells
Lai, S. Y., & Grandis, J. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1190 · Cited by 41
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch, R., James, R. D., Wilkinson, P. M., et al. (2006) · PubMed · Cited by 40
Charu, V., Belani, C. P., Gill, A. N., Bhatt, M., Tomita, D. K., Rossi, G., & Ben-Jacob, A. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-727 · Cited by 33
Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells
Kumar, S., Yu, H., Fong, D., Ács, G., & Xu, X. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000222594.60611.c3 · Cited by 32
Cited by
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.04.025 · Cited by 3,418
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000509 · Cited by 3,109
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
Ghany, M. G., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2009) · Hepatology · doi:10.1002/hep.22759 · Cited by 2,973
Epidemiology of cancer-associated venous thrombosis
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013) · Blood · doi:10.1182/blood-2013-04-460121 · Cited by 1,205
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., Drazner, M. H., Filippatos, G. S., Fonarow, G. C., Givertz, M. M., et al. (2017) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2017.04.014 · Cited by 770
Metadata
- Authors
- Bennett, C. L.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2008-02-27
- Volume
- 299
- Issue
- 8
- Pages
- 914
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2150250025
- Cited by
- 731
- References
- 43
- FWCI
- 61.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.